Circio Holding (LSE:0RIS) - Hisse Senedi Fiyatı, Haberler ve Analizler

0RIS Stoklara Genel Bakış

A biotechnology company, develops novel circular RNA and immunotherapy medicines. Daha fazla detay

0RIS temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Kazançların yılda 86.5% oranında artması öngörülüyor

Risk Analizi

Anlamlı bir piyasa değeri yok ( NOK56M )

Geliri 1 milyon ABD dolarından az ( NOK10M )

Negatif hissedar öz sermayesi

Hisse senetleri oldukça likit değildir

+ 2 daha fazla risk

Circio Holding ASA Rakipler

Theracryf

AIM:TCF

UK£2.3m

BSF Enterprise

LSE:BSFA

UK£3.4m

Genflow Biosciences

LSE:GENF

UK£6.3m

Verici Dx

AIM:VRCI

UK£8.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Circio Holding
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	NOK 11.20
52 Haftanın En Yüksek Seviyesi	NOK 37.20
52 Haftanın En Düşük Seviyesi	NOK 11.12
Beta	2.06
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	n/a
33 Yıllık Değişim	-96.14%
5 Yıllık Değişim	-95.71%
Halka arzdan bu yana değişim	-96.27%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0RIS	GB Biotechs	GB Pazar
7D	0%	-6.0%	-0.3%
1Y	n/a	-22.4%	6.1%

Getiri vs. Endüstri: 0RIS un UK Biotechs sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: 0RIS un UK Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is 0RIS's price volatile compared to industry and market?
0RIS volatility
0RIS Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.5%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0RIS son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 0RIS 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2010	17	Erik Wiklund	www.circio.com

Circio Holding ASA Temel Bilgiler Özeti

Circio Holding'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0RIS temel i̇stati̇sti̇kler
Piyasa değeri	NOK 56.45m
Kazançlar(TTM)	-NOK 449.26m
Gelir(TTM)	NOK 10.00m

5.6x

P/S Oranı

-0.1x

F/K Oranı

0RIS aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0RIS gelir tablosu (TTM)
Gelir	NOK 10.00m
Gelir Maliyeti	NOK 0
Brüt Kâr	NOK 10.00m
Diğer Giderler	NOK 459.26m
Kazançlar	-NOK 449.26m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

Feb 15, 2024

Hisse başına kazanç (EPS)	-62.71
Brüt Marj	100.00%
Net Kâr Marjı	-4,491.69%
Borç/Özkaynak Oranı	-135.9%

0RIS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0RIS Stoklara Genel Bakış

Ödüller

Risk Analizi

Circio Holding ASA Rakipler

AIM:TCF

UK£2.3m

LSE:BSFA

UK£3.4m

LSE:GENF

UK£6.3m

AIM:VRCI

UK£8.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Circio Holding ASA Presents Circvec Circular RNA in Vivo Expression Proof-Of-Concept Data At ESGCT 2024 Annual Meeting

Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 60 million.

Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus

Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University

Circio Holding ASA, Annual General Meeting, Jun 05, 2024

Recent updates

Circio Holding ASA Presents Circvec Circular RNA in Vivo Expression Proof-Of-Concept Data At ESGCT 2024 Annual Meeting

Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 60 million.

Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus

Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University

Circio Holding ASA, Annual General Meeting, Jun 05, 2024

IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration

Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital

New major risk - Financial position

High number of new directors

New major risk - Negative shareholders equity

High number of new directors

High number of new directors

Forecast to breakeven in 2024

High number of new directors

High number of new directors

Targovax Announces That the TG01 Study in Multiple Myeloma At Oslo University Hospital Has Received Regulatory Approvals to Proceed

Targovax ASA to Report Q4, 2023 Results on Feb 15, 2024

No longer forecast to breakeven

High number of new directors

Targovax ASA Completes ONCOS-102 Phase 1b Study in PD-1 CPI Resistant Advanced Melanoma Has Been Published in the Oncology Journal Clinical Cancer Research

No longer forecast to breakeven

High number of new directors

Targovax ASA Receives Approval to Proceed with the Oncos-102 Phase 2 Melanoma Study from the US FDA

No longer forecast to breakeven

High number of new directors

High number of new directors

Targovax ASA Announces that the FDA Grant Authorization to Initiate Clinical Trials with the Enhanced TG01 RAS Vaccine in the USA

High number of new directors

Targovax ASA Announces Board Changes

High number of new directors

Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022

Targovax ASA Announces ONCOS-102 Achieves 25.0 Months Median Overall Survival in First Line Mesothelioma

Chief Executive Officer recently bought kr201k worth of stock

High number of new directors

High number of new directors

Chief Financial Officer Torbjørn Furuseth has left the company

High number of new directors

Targovax Receives Fast Track Designation for Oncos-102 in Melanoma

Targovax Announces Completed Enrollment in the Phase 1/2 Trial with ONCOS-102 in Combination with Durvalumab in Patients with Advanced Colorectal Cancer with Peritoneal Malignancies

Targovax ASA's ONCOS-102 Mesothelioma 24-Month Data Shows Class-Leading Median Overall Survival

Targovax ASA Announces Board Changes

Targovax Granted US Patent for Oncos-102 in Combination with Checkpoint Inhibitors

Continued Survival Benefit in Targovax's ONCOS-102 Trial in Mesothelioma At the 21-Month Follow-Up

Targovax ASA Receives Fast-Track Designation for ONCOS-102

Targovax ASA and Papyrus Therapeutics Enter Research Collaboration to Develop Novel ONCOS Viruses with Receptor Tyrosine Kinase (RTK) Inhibitor Functionality

Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Circio Holding ASA Temel Bilgiler Özeti

5.6x

-0.1x

Kazanç ve Gelir